Concepedia

Laurence Catley

LC

Statistics

Publications

34

Citations

4.9K

H-Index

30

Active since

2001

Affiliations

Dana-Farber Cancer Institute(Current)

Harvard University

Novartis (Switzerland)

VA Boston Healthcare System

Brigham and Women's Hospital

Laurence Catley is an author at Dana-Farber Cancer Institute specializing in medicine, multiple myeloma, and oncology.

Publications per year

2001–2013

34

Publications

34

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

Paul G. Richardson, Robert Schlossman, Edie Weller et al. · Blood · 2002 · 804 citations · Full text

Medicine, Immunology, Pharmacology +12

Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.

Richard LeBlanc, Laurence Catley, Teru Hideshima et al. · PubMed · 2002 · 456 citations

Medicine, Oncology, Pharmacology +13

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

Teru Hideshima, Laurence Catley, Hiroshi Yasui et al. · Blood · 2006 · 421 citations · Full text

Medicine, Oncology, Pharmacology +15

Immunomodulatory drug costimulates T cells via the B7-CD28 pathway

Richard LeBlanc, Teru Hideshima, Laurence Catley et al. · Blood · 2003 · 286 citations

Life Sciences, Cell Biology, Immunology +14

NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma

Laurence Catley, Ellen Weisberg, Yu-Tzu Tai et al. · Blood · 2003 · 219 citations · Full text

Medicine, Molecular Biology, Oncology +12

1–5 of 34